Drug Profile
Research programme: biotherapeutics and vaccines - Symbigene
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Symbigene
- Class Peptides; Proteins; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Herpes simplex virus infections; Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (Vaginal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections(Prevention) in USA (Vaginal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (PO)